- Home
- KPRX vs PRPO Comparison
KPRX vs PRPO Comparison
Compare KPRX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- PRPO
- Stock Information
- Founded
- KPRX 1998
- PRPO N/A
- Country
- KPRX United States
- PRPO United States
- Employees
- KPRX N/A
- PRPO N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- KPRX Health Care
- PRPO Industrials
- Exchange
- KPRX Nasdaq
- PRPO Nasdaq
- Market Cap
- KPRX 10.0M
- PRPO 8.8M
- IPO Year
- KPRX N/A
- PRPO N/A
- Fundamental
- Price
- KPRX $3.26
- PRPO $5.79
- Analyst Decision
- KPRX Strong Buy
- PRPO
- Analyst Count
- KPRX 1
- PRPO 0
- Target Price
- KPRX $10.00
- PRPO N/A
- AVG Volume (30 Days)
- KPRX 34.9K
- PRPO 5.7K
- Earning Date
- KPRX 11-08-2024
- PRPO 11-06-2024
- Dividend Yield
- KPRX N/A
- PRPO N/A
- EPS Growth
- KPRX N/A
- PRPO N/A
- EPS
- KPRX 1.69
- PRPO N/A
- Revenue
- KPRX $16,020,000.00
- PRPO $17,411,000.00
- Revenue This Year
- KPRX N/A
- PRPO $75.18
- Revenue Next Year
- KPRX N/A
- PRPO N/A
- P/E Ratio
- KPRX $2.04
- PRPO N/A
- Revenue Growth
- KPRX N/A
- PRPO 31.31
- 52 Week Low
- KPRX $3.00
- PRPO $4.31
- 52 Week High
- KPRX $8.98
- PRPO $7.30
- Technical
- Relative Strength Index (RSI)
- KPRX 43.44
- PRPO 41.19
- Support Level
- KPRX $3.30
- PRPO $5.72
- Resistance Level
- KPRX $4.04
- PRPO $6.48
- Average True Range (ATR)
- KPRX 0.28
- PRPO 0.24
- MACD
- KPRX -0.01
- PRPO 0.01
- Stochastic Oscillator
- KPRX 7.14
- PRPO 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.